Login

A Mixed Start for BlossomHill BlossomHill Therapeutics Inc., a company dedicated to advancing cancer treatments, raised $150 million in an upsized IPO, yet its shares fell 1.6% on the first day of trading. This decline reflects a broader skepticism among investors towards biotech stocks, particularly in an environment marked by economic fluctuations and regulatory scrutiny. […]